AAV vectors are promising candidates for human gene therapy. The inability of AAV to bind cells lacking the heparan sulfate proteoglycan, however, has limited the range of cells that can be targeted. Using a bispecific antibody that recognizes the platelet–specific αIIbβ3 integrin and the AAV capsid structure, Bartlett et al. have successfully transduced megakaryocyte cell lines recalcitrant to infection by wild–type AAV (p. 181). Interestingly, the bispecific antibody also appeared to reduce the endogenous tropism of the AAV vector for heparan sulfate bearing cells.
Rights and permissions
About this article
Cite this article
Marshall, A. Fab direction for AAV. Nat Biotechnol 17, 121 (1999). https://doi.org/10.1038/6105
Issue Date:
DOI: https://doi.org/10.1038/6105